Literature DB >> 7777531

Reciprocal modulations between p53 and Tat of human immunodeficiency virus type 1.

C J Li1, C Wang, D J Friedman, A B Pardee.   

Abstract

Infection by human immunodeficiency virus type 1 (HIV-1) causes acquired immunodeficiency syndrome (AIDS) after a long clinical latency. This disease is associated with a spectrum of cancers. Here we report that wild-type p53 is a potent suppressor of Tat, a major transactivator of HIV-1. Reciprocally, Tat inhibits the transcription of p53. Downregulation of p53 by upregulated tat may be important for the establishment of productive viral infection in a cell and also may be involved in the development of AIDS-related malignancies.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7777531      PMCID: PMC41714          DOI: 10.1073/pnas.92.12.5461

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  29 in total

1.  Activation of the human immunodeficiency virus type 1 long terminal repeat by transforming mutants of human p53.

Authors:  M A Subler; D W Martin; S Deb
Journal:  J Virol       Date:  1994-01       Impact factor: 5.103

2.  P53: a determinant of the cell cycle response to DNA damage.

Authors:  M B Kastan
Journal:  Adv Exp Med Biol       Date:  1993       Impact factor: 2.622

3.  Wild-type mouse p53 down-regulates transcription from different virus enhancer/promoters.

Authors:  P Jackson; E Bos; A W Braithwaite
Journal:  Oncogene       Date:  1993-03       Impact factor: 9.867

Review 4.  Does HIV-1 Tat induce a change in viral initiation rights?

Authors:  B R Cullen
Journal:  Cell       Date:  1993-05-07       Impact factor: 41.582

5.  The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53.

Authors:  M Scheffner; J M Huibregtse; R D Vierstra; P M Howley
Journal:  Cell       Date:  1993-11-05       Impact factor: 41.582

6.  Systemic expression of HIV-1 tat gene in transgenic mice induces endothelial proliferation and tumors of different histotypes.

Authors:  A Corallini; G Altavilla; L Pozzi; F Bignozzi; M Negrini; P Rimessi; F Gualandi; G Barbanti-Brodano
Journal:  Cancer Res       Date:  1993-11-15       Impact factor: 12.701

7.  Camptothecin inhibits Tat-mediated transactivation of type 1 human immunodeficiency virus.

Authors:  C J Li; C Wang; A B Pardee
Journal:  J Biol Chem       Date:  1994-03-11       Impact factor: 5.157

8.  Direct interaction of human TFIID with the HIV-1 transactivator tat.

Authors:  F Kashanchi; G Piras; M F Radonovich; J F Duvall; A Fattaey; C M Chiang; R G Roeder; J N Brady
Journal:  Nature       Date:  1994-01-20       Impact factor: 49.962

9.  Hepatitis B virus X protein inhibits p53 sequence-specific DNA binding, transcriptional activity, and association with transcription factor ERCC3.

Authors:  X W Wang; K Forrester; H Yeh; M A Feitelson; J R Gu; C C Harris
Journal:  Proc Natl Acad Sci U S A       Date:  1994-03-15       Impact factor: 11.205

10.  Three inhibitors of type 1 human immunodeficiency virus long terminal repeat-directed gene expression and virus replication.

Authors:  C J Li; L J Zhang; B J Dezube; C S Crumpacker; A B Pardee
Journal:  Proc Natl Acad Sci U S A       Date:  1993-03-01       Impact factor: 12.779

View more
  40 in total

Review 1.  New insights for FOXO and cell-fate decision in HIV infection and HIV associated neurocognitive disorder.

Authors:  Min Cui; Yunlong Huang; Yong Zhao; Jialin Zheng
Journal:  Adv Exp Med Biol       Date:  2009       Impact factor: 2.622

Review 2.  The rising challenge of non-AIDS-defining cancers in HIV-infected patients.

Authors:  John F Deeken; Angelique Tjen-A-Looi; Michelle A Rudek; Catherine Okuliar; Mary Young; Richard F Little; Bruce J Dezube
Journal:  Clin Infect Dis       Date:  2012-07-09       Impact factor: 9.079

Review 3.  Lung cancer in HIV-infected patients in the combination antiretroviral treatment era.

Authors:  José Moltó; Teresa Moran; Guillem Sirera; Bonaventura Clotet
Journal:  Transl Lung Cancer Res       Date:  2015-12

4.  Potential of Radiation-Induced Cellular Stress for Reactivation of Latent HIV-1 and Killing of Infected Cells.

Authors:  Sergey Iordanskiy; Fatah Kashanchi
Journal:  AIDS Res Hum Retroviruses       Date:  2016-02       Impact factor: 2.205

5.  Identification of specific molecular structures of human immunodeficiency virus type 1 Tat relevant for its biological effects on vascular endothelial cells.

Authors:  S Mitola; R Soldi; I Zanon; L Barra; M I Gutierrez; B Berkhout; M Giacca; F Bussolino
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

6.  HIV-1 Tat targets Tip60 to impair the apoptotic cell response to genotoxic stresses.

Authors:  Edwige Col; Cécile Caron; Christine Chable-Bessia; Gaelle Legube; Sylvie Gazzeri; Yasuhiko Komatsu; Minoru Yoshida; Monsef Benkirane; Didier Trouche; Saadi Khochbin
Journal:  EMBO J       Date:  2005-07-07       Impact factor: 11.598

7.  Rational design of p53, an intrinsically unstructured protein, for the fabrication of novel molecular sensors.

Authors:  Melissa L Geddie; Taryn L O'Loughlin; Kristen K Woods; Ichiro Matsumura
Journal:  J Biol Chem       Date:  2005-08-23       Impact factor: 5.157

Review 8.  Knitting and untying the protein network: modulation of protein ensembles as a therapeutic strategy.

Authors:  Susana Gordo; Ernest Giralt
Journal:  Protein Sci       Date:  2009-03       Impact factor: 6.725

9.  HIV-1 Tat regulates cyclin B1 by promoting both expression and degradation.

Authors:  Shi-Meng Zhang; Yi Sun; Rong Fan; Qin-Zhi Xu; Xiao-Dan Liu; Xiangming Zhang; Ya Wang; Ping-Kun Zhou
Journal:  FASEB J       Date:  2009-10-13       Impact factor: 5.191

10.  Tat-induced FOXO3a is a key mediator of apoptosis in HIV-1-infected human CD4+ T lymphocytes.

Authors:  Alicja Dabrowska; Nayoung Kim; Anna Aldovini
Journal:  J Immunol       Date:  2008-12-15       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.